{"id":"omega","rwe":[],"_fda":{"id":"774e24ef-b517-4346-9c90-c74cde9d8f06","set_id":"034045d6-5308-4701-b97b-8873e053ec17","openfda":{"unii":["D87YGH4Z0Q"],"route":["ORAL"],"rxcui":["577208"],"spl_id":["774e24ef-b517-4346-9c90-c74cde9d8f06"],"brand_name":["Omega-3-acid ethyl esters"],"spl_set_id":["034045d6-5308-4701-b97b-8873e053ec17"],"package_ndc":["72162-1310-2"],"product_ndc":["72162-1310"],"generic_name":["OMEGA-3-ACID ETHYL ESTERS"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["OMEGA-3-ACID ETHYL ESTERS"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA207420"],"original_packager_product_ndc":["31722-936"]},"version":"100","pregnancy":["8.1 Pregnancy Risk Summary The available data from published case reports and the pharmacovigilance database on the use of omega-3-acid ethyl esters in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development when given at doses 5 times the maximum recommended human dose (MRHD) of 4 grams/day, based on a body surface area comparison. Omega-3-acid ethyl esters given orally to rats and rabbits during organogenesis was not teratogenic at clinically relevant exposures, based on body surface area comparison (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data: In female rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) beginning 2 weeks prior to mating through lactation, no adverse effects were observed at 2,000 mg/kg/day (5 times the MRHD based on body surface area [mg/m 2 ]). In a dose-ranging study, female rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) beginning 2 weeks prior to mating through Postpartum Day 7 had decreased live births (20% reduction) and pup survival to Postnatal Day 4 (40% reduction) at or greater than 3,000 mg/kg/day in the absence of maternal toxicity at 3,000 mg/kg/day (7 times the MRHD based on body surface area [mg/m 2 ]). In pregnant rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses at a maternally toxic dose (increased food consumption) of 6,000 mg/kg/day (14 times the MRHD based on body surface area [mg/m 2 ]). In pregnant rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) from Gestation Day 14 through Lactation Day 21, no adverse effects were observed at 2,000 mg/kg/day (5 times the MRHD based on body surface area [mg/m 2 ]). In pregnant rabbits given oral doses of omega-3-acid ethyl esters (375, 750, or 1,500 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses given 375 mg/kg/day (2 times the MRHD based on body surface area [mg/m 2 ]). However, at higher doses, increases in fetal skeletal variations and reduced fetal growth were evident at maternally toxic doses (reduced food consumption and body weight gain) greater than or equal to 750 mg/kg/day (4 times the MRHD), and embryolethality was evident at 1,500 mg/kg/day (7 times the MRHD)."],"description":["11 DESCRIPTION Omega-3-acid ethyl esters, USP, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of omega-3-acid ethyl esters contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg). The empirical formula of EPA ethyl ester is C 22 H 34 O 2 , and the molecular weight of EPA ethyl ester is 330.51. The structural formula of EPA ethyl ester is: The empirical formula of DHA ethyl ester is C 24 H 36 O 2 , and the molecular weight of DHA ethyl ester is 356.55. The structural formula of DHA ethyl ester is: Omega-3-acid ethyl esters capsules, USP also contain the following inactive ingredients: gelatin, glycerin, 4.4 mg α-tocopherol, soybean oil and purified water. The capsules are printed with white imprinting ink containing titanium dioxide, hypromellose 2910 and propylene glycol."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Omega-3-acid ethyl esters capsules, USP are supplied as 1 gram clear, transparent oblong capsules containing clear to light yellow colored solution imprinted with ‘AT 132’ with white ink. NDC: 72162-1310-2: 120 Capsules in a BOTTLE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. Protect from light. Keep out of reach of children. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"geriatric_use":["8.5 Geriatric Use A limited number of subjects older than 65 years were enrolled in the clinical trials of omega-3-acid ethyl esters. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20231006","nursing_mothers":["8.2 Lactation Risk Summary Published studies have detected omega-3 fatty acids, including EPA and DHA, in human milk. Lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk. There are no data available on the effects of omega-3 fatty acid ethyl esters on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for omega-3-acid ethyl esters and any potential adverse effects on the breastfed child from omega-3-acid ethyl esters or from the underlying maternal condition."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Severe Hypertriglyceridemia The effects of omega-3-acid ethyl esters 4 grams per day were assessed in 2 randomized, placebo-controlled, double-blind, parallel-group trials of 84 adult subjects (42 on omega-3-acid ethyl esters, 42 on placebo) with very high TG levels. Subjects whose baseline TG levels were between 500 and 2,000 mg/dL were enrolled in these 2 trials of 6 and 16 weeks’ duration. The median TG and LDL-C levels in these subjects were 792 mg/dL and 100 mg/dL, respectively. Median high-density lipoprotein cholesterol (HDL-C) level was 23.0 mg/dL. The changes in the major lipoprotein lipid parameters for the groups receiving omega-3-acid ethyl esters or placebo are shown in Table 2. Table 2. Median Baseline and Percent Change from Baseline in Lipid Parameters in Subjects with Severe Hypertriglyceridemia (≥500 mg/dL) BL = Baseline (mg/dL); % Change = Median Percent Change from Baseline; Difference = omega-3-acid ethyl esters Median % Change – Placebo Median % Change. TC = Total cholesterol. VLDL-C = Very-low-density lipoprotein (VLDL) cholesterol. Omega-3-acid ethyl esters 4 grams per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with omega-3-acid ethyl esters to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively. The effect of omega-3-acid ethyl esters on the risk of pancreatitis has not been determined. The effect of omega-3-acid ethyl esters on cardiovascular mortality and morbidity has not been determined."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption In healthy volunteers and in subjects with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters induced significant dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters. Specific Populations Age: Uptake of EPA and DHA into serum phospholipids in subjects treated with omega-3-acid ethyl esters was independent of age (younger than 49 years versus 49 years and older). Male and Female Patients: Females tended to have more uptake of EPA into serum phospholipids than males. The clinical significance of this is unknown. Pediatric Patients: Pharmacokinetics of omega-3-acid ethyl esters have not been studied. Patients with Renal or Hepatic Impairment: Omega-3-acid ethyl esters has not been studied in patients with renal or hepatic impairment. Drug Interaction Studies Simvastatin: In a 14-day trial of 24 healthy adult subjects, daily coadministration of simvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect the extent (AUC) or rate (C max ) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin, at steady state. Atorvastatin: In a 14-day trial of 50 healthy adult subjects, daily coadministration of atorvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or C max of exposure to atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady state. Rosuvastatin: In a 14-day trial of 48 healthy adult subjects, daily coadministration of rosuvastatin 40 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or C max of exposure to rosuvastatin at steady state. In vitro studies using human liver microsomes indicated that clinically significant cytochrome P450-mediated inhibition by EPA/DHA combinations are not expected in humans."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions (incidence >3% and greater than placebo) were eructation, dyspepsia, and taste perversion. To report SUSPECTED ADVERSE REACTIONS, contact Camber Pharmaceuticals Inc., at 1-866-495-8330 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported in at least 3% of subjects treated with omega-3-acid ethyl esters and at a greater rate than placebo based on pooled data across 23 clinical trials are listed in Table 1. Table 1. Adverse Reactions Occurring at Incidence ≥ 3% and Greater than Placebo in Clinical Trials of Omega-3-acid ethyl esters capsules Adverse Reactions a Omega-3-acid ethyl esters (n = 655) Placebo (n = 370) n % n % Eructation 29 4 5 1 Dyspepsia 22 3 6 2 Taste perversion 27 4 1 <1 a Trials included subjects with hypertriglyceridemia and severe hypertriglyceridemia. Additional adverse reactions from clinical trials are listed below: Digestive System Constipation, gastrointestinal disorder, and vomiting. Metabolic and Nutritional Disorders Increased ALT and increased AST. Skin Pruritus and rash. 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of omega-3-acid ethyl esters capsules. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure. The following events have been reported: anaphylactic reaction, hemorrhagic diathesis, urticaria."],"contraindications":["4 CONTRAINDICATIONS Omega-3-acid ethyl esters capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters or any of its components. Omega-3-acid ethyl esters capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters or any of its components."],"drug_interactions":["7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. (7.1) 7.1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically."],"mechanism_of_action":["12.1 Mechanism of Action The mechanism of action of omega-3-acid ethyl esters is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-acid ethyl esters may reduce the synthesis of TG in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of omega-3-acid ethyl esters is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-acid ethyl esters may reduce the synthesis of TG in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids. 12.3 Pharmacokinetics Absorption In healthy volunteers and in subjects with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters induced significant dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters. Specific Populations Age: Uptake of EPA and DHA into serum phospholipids in subjects treated with omega-3-acid ethyl esters was independent of age (younger than 49 years versus 49 years and older). Male and Female Patients: Females tended to have more uptake of EPA into serum phospholipids than males. The clinical significance of this is unknown. Pediatric Patients: Pharmacokinetics of omega-3-acid ethyl esters have not been studied. Patients with Renal or Hepatic Impairment: Omega-3-acid ethyl esters has not been studied in patients with renal or hepatic impairment. Drug Interaction Studies Simvastatin: In a 14-day trial of 24 healthy adult subjects, daily coadministration of simvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect the extent (AUC) or rate (C max ) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin, at steady state. Atorvastatin: In a 14-day trial of 50 healthy adult subjects, daily coadministration of atorvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or C max of exposure to atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady state. Rosuvastatin: In a 14-day trial of 48 healthy adult subjects, daily coadministration of rosuvastatin 40 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or C max of exposure to rosuvastatin at steady state. In vitro studies using human liver microsomes indicated that clinically significant cytochrome P450-mediated inhibition by EPA/DHA combinations are not expected in humans."],"indications_and_usage":["1 INDICATIONS AND USAGE Omega-3-acid ethyl esters capsules are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters capsules. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of TG-lowering drug therapy. Limitations of Use: The effect of omega-3-acid ethyl esters capsules on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters on cardiovascular mortality and morbidity has not been determined. Omega-3-acid ethyl esters capsules are a combination of ethyl esters of omega 3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. (1) Limitations of Use: The effect of omega-3-acid ethyl esters on the risk for pancreatitis has not been determined. (1) The effect of omega-3-acid ethyl esters on cardiovascular mortality and morbidity has not been determined. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. (5.1) Omega-3-acid ethyl esters capsules may increase levels of low-density lipoprotein (LDL). Monitor LDL levels periodically during therapy. (5.1) Use with caution in patients with known hypersensitivity to fish and/or shellfish. (5.2) There is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3) 5.1 Monitoring: Laboratory Tests In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with omega-3-acid ethyl esters capsules. In some patients, increases in ALT levels without a concurrent increase in AST levels were observed. In some patients, omega-3-acid ethyl esters increases low-density lipoprotein cholesterol (LDL-C) levels. LDL-C levels should be monitored periodically during therapy with omega-3-acid ethyl esters. Laboratory studies should be performed periodically to measure the patient’s TG levels during therapy with omega-3-acid ethyl esters. 5.2 Fish Allergy Omega-3-acid ethyl esters contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources. It is not known whether patients with allergies to fish and/or shellfish, are at increased risk of an allergic reaction to omega-3-acid ethyl esters. Omega-3-acid ethyl esters should be used with caution in patients with known hypersensitivity to fish and/or shellfish. 5.3 Recurrent Atrial Fibrillation (AF) or Flutter In a double-blind, placebo-controlled trial of 663 subjects with symptomatic paroxysmal AF (n = 542) or persistent AF (n = 121), recurrent AF or flutter was observed in subjects randomized to omega-3-acid ethyl esters who received 8 grams/day for 7 days and 4 grams/day thereafter for 23 weeks at a higher rate relative to placebo. Subjects in this trial had median baseline TG levels of 127 mg/dL, had no substantial structural heart disease, were taking no anti-arrhythmic therapy (rate control permitted), and were in normal sinus rhythm at baseline. At 24 weeks, in the paroxysmal AF stratum, there were 129 (47%) first recurrent symptomatic AF or flutter events on placebo and 141 (53%) on omega-3-acid ethyl esters (primary endpoint, HR: 1.19; 95% CI: 0.93, 1.35). In the persistent AF stratum, there were 19 (35%) events on placebo and 34 (52%) events on omega-3-acid ethyl esters (HR: 1.63; 95% CI: 0.91, 2.18). For both strata combined, the HR was 1.25; 95% CI: 1.00, 1.40. Although the clinical significance of these results is uncertain, there is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic AF or flutter in patients with paroxysmal or persistent AF, particularly within the first 2 to 3 months of initiating therapy. Omega-3-acid ethyl esters capsules are not indicated for the treatment of AF or flutter."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated with omega-3-acid ethyl esters for 101 weeks and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 grams/day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice. Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without metabolic activation in the bacterial mutagenesis (Ames) test with Salmonella typhimurium and Escherichia coli or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Omega-3-acid ethyl esters were negative in the in vivo mouse micronucleus assay. In a rat fertility study with oral doses of 100, 600, and 2,000 mg/kg/day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to mating and through lactation. No adverse effect on fertility was observed at 2,000 mg/kg/day (5 times the MRHD of 4 grams/day based on body surface area [mg/m 2 ])."],"adverse_reactions_table":["<table width=\"60%\"><colgroup><col width=\"20%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/><col width=\"10%\"/></colgroup><tbody><tr><td styleCode=\"Botrule Lrule Rrule\" rowspan=\"2\" align=\"left\" valign=\"middle\"> <content styleCode=\"bold\">Adverse </content><content styleCode=\"bold\">Reactions<sup>a</sup></content></td><td styleCode=\"Botrule Rrule\" colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Omega-3-acid ethyl esters </content><content styleCode=\"bold\"/> <content styleCode=\"bold\">(n = 655)</content></td><td styleCode=\"Botrule Rrule\" colspan=\"2\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n = 370)</content></td></tr><tr><td styleCode=\"Botrule Rrule\" align=\"center\"><content styleCode=\"bold\">n</content></td><td styleCode=\"Botrule Rrule\" align=\"center\"><content styleCode=\"bold\">%</content></td><td styleCode=\"Botrule Rrule\" align=\"center\"><content styleCode=\"bold\">n</content></td><td styleCode=\"Botrule Rrule\" align=\"center\"><content styleCode=\"bold\">%</content></td></tr><tr><td styleCode=\"Lrule Rrule\"> Eructation</td><td styleCode=\"Rrule\" align=\"center\">29</td><td styleCode=\"Rrule\" align=\"center\">4</td><td styleCode=\"Rrule\" align=\"center\">5</td><td styleCode=\"Rrule\" align=\"center\">1</td></tr><tr><td styleCode=\"Lrule Rrule\"> Dyspepsia</td><td styleCode=\"Rrule\" align=\"center\">22</td><td styleCode=\"Rrule\" align=\"center\">3</td><td styleCode=\"Rrule\" align=\"center\">6</td><td styleCode=\"Rrule\" align=\"center\">2</td></tr><tr><td styleCode=\"Lrule Rrule\"> Taste perversion</td><td styleCode=\"Rrule\" align=\"center\">27</td><td styleCode=\"Rrule\" align=\"center\">4</td><td styleCode=\"Rrule\" align=\"center\">1</td><td styleCode=\"Rrule\" align=\"center\">&lt;1</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Information for Patients Omega-3-acid ethyl esters should be used with caution in patients with known sensitivity or allergy to fish and/or shellfish [see Warnings and Precautions (5.2)] . Advise patients that use of lipid-regulating agents does not reduce the importance of adhering to diet [see Dosage and Administration (2)] . Advise patients not to alter omega-3-acid ethyl esters capsules in any way and to ingest intact capsules only [see Dosage and Administration (2)] . Instruct patients to take omega-3-acid ethyl esters as prescribed. If a dose is missed, advise patients to take it as soon as they remember. However, if they miss one day of omega-3-acid ethyl esters, they should not double the dose when they take it. Manufactured by: Ascent Pharmaceuticals, Inc. Central Islip, NY 11722 Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 Rev: 05/21"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Assess TG levels carefully before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, medications) of high TG levels and manage as appropriate [see Indications and Usage (1)] . Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, and should continue this diet during treatment with omega-3-acid ethyl esters. In clinical studies, omega-3-acid ethyl esters capsules was administered with meals. The daily dose of omega-3-acid ethyl esters capsules is 4 grams per day. The daily dose may be taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily). Patients should be advised to swallow omega-3-acid ethyl esters capsules whole. Do not break open, crush, dissolve, or chew omega-3-acid ethyl esters capsules. The daily dose of omega-3-acid ethyl esters capsules is 4 grams per day taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily). (2) Patients should be advised to swallow omega-3-acid ethyl esters capsules whole. Do not break open, crush, dissolve, or chew omega-3-acid ethyl esters capsules. (2)"],"spl_product_data_elements":["Omega-3-acid ethyl esters Omega-3-acid ethyl esters OMEGA-3-ACID ETHYL ESTERS OMEGA-3 FATTY ACIDS GELATIN, UNSPECIFIED GLYCERIN .ALPHA.-TOCOPHEROL SOYBEAN OIL WATER TITANIUM DIOXIDE HYPROMELLOSE, UNSPECIFIED PROPYLENE GLYCOL Clear to light yellow Oblong AT132 DHA-structure EPA-structure Table-2 common side effects"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Omega-3-acid ethyl esters capsules, USP are supplied as 1 gram clear, transparent oblong capsules containing clear to light yellow colored solution imprinted with ‘AT 132’ with white ink. Capsules: 1 gram"],"spl_patient_package_insert":["PATIENT INFORMATION Omega-3-acid ethyl esters (oh-MAY-ga 3 AS-id eth-il es-ters) Capsules, USP What are omega-3-acid ethyl esters capsules? Omega-3-acid ethyl esters capsules are a prescription medicine used along with a low-fat and low-cholesterol diet to lower very high triglyceride (fat) levels in adults. It is not known if omega-3-acid ethyl esters changes your risk of having inflammation of your pancreas (pancreatitis). It is not known if omega-3-acid ethyl esters prevents you from having a heart attack or stroke. It is not known if omega-3-acid ethyl esters are safe and effective in children. Who should not take omega-3-acid ethyl esters capsules? Do not take omega-3-acid ethyl esters capsules if you are allergic to omega-3-acid ethyl esters or any of the ingredients in omega-3-acid ethyl esters capsules. See the end of this leaflet for a complete list of ingredients in omega-3-acid ethyl esters capsules. Before taking omega-3-acid ethyl esters, tell your healthcare provider about all of your medical conditions, including if you: have diabetes. have a low thyroid problem (hypothyroidism). have a liver problem. have a pancreas problem. have a certain heart rhythm problem called atrial fibrillation or flutter. are allergic to fish or shellfish. It is not known if people who are allergic to fish or shellfish are also allergic to omega-3-acid ethyl esters capsules. are pregnant or plan to become pregnant. It is not known if omega-3-acid ethyl esters will harm your unborn baby. are breastfeeding or plan to breastfeed. Omega-3-acid ethyl esters can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take omega-3-acid ethyl esters capsules. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Omega-3-acid ethyl esters capsules can interact with certain other medicines that you are taking. Using omega-3-acid ethyl esters capsules with medicines that affect blood clotting (anticoagulants or blood thinners) may cause serious side effects. How should I take omega-3-acid ethyl esters capsules? Take omega-3-acid ethyl esters capsules exactly as your healthcare provider tells you to take it. You should not take more than 4 capsules of omega-3-acid ethyl esters capsules each day. Either take all 4 capsules at one time or 2 capsules two times a day. Do not change your dose or stop omega-3-acid ethyl esters capsules without talking to your healthcare provider. Take omega-3-acid ethyl esters capsules with food. Take omega-3-acid ethyl esters capsules whole. Do not break, open, crush, dissolve, or chew omega-3-acid ethyl esters capsules before swallowing. If you cannot swallow omega-3-acid ethyl esters capsules whole, tell your healthcare provider. You may need a different medicine. If you miss a dose of omega-3-acid ethyl esters capsules, take the missed dose as soon as you remember. If you miss one day of omega-3-acid ethyl esters capsules, do not double your dose the next time you take it. Your healthcare provider may start you on a cholesterol-lowering diet before giving you omega-3-acid ethyl esters capsules. Stay on this diet while taking omega-3-acid ethyl esters capsules. Your healthcare provider should do blood tests to check your triglyceride, bad cholesterol (LDL-C), and liver function (ALT and AST) levels while you take omega-3-acid ethyl esters capsules. What are the possible side effects of omega-3-acid ethyl esters capsules? Omega-3-acid ethyl esters capsules may cause serious side effects, including: changes in certain blood tests. Omega-3-acid ethyl esters may cause an increase in the results of blood tests used to check your liver function and your bad cholesterol levels. increased risk of a heart rhythm problem in people who have a heart rhythm problem. Omega-3-acid ethyl esters may cause an increase in the frequency of a heart rhythm problem (atrial fibrillation or flutter), especially in the first few months of taking omega-3-acid ethyl esters, if you already have a heart rhythm problem. The most common side effects of omega-3-acid ethyl esters include: These are not all the possible side effects of omega-3-acid ethyl esters. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store omega-3-acid ethyl esters capsules? Store omega-3-acid ethyl esters capsules at room temperature between 68°F to 77°F (20°C to 25°C). Do not freeze omega-3-acid ethyl esters capsules. Safely throw away medicine that is out of date or no longer needed. Keep omega-3-acid ethyl esters capsules and all medicines out of the reach of children. General information about the safe and effective use of omega-3-acid ethyl esters capsules. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use omega-3-acid ethyl esters capsules for a condition for which it was not prescribed. Do not give omega-3-acid ethyl esters capsules to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about omega-3-acid ethyl esters capsules that is written for health professionals. What are the ingredients in omega-3-acid ethyl esters capsules, USP? Active Ingredient: omega-3-acid ethyl esters, mostly EPA and DHA. Inactive Ingredients: gelatin, glycerin, 4.4 mg α-tocopherol, soybean oil and purified water. The capsules are printed with white imprinting ink containing titanium dioxide, hypromellose 2910 and propylene glycol. Manufactured by : Ascent Pharmaceuticals, Inc. Central Islip, NY 11722 Manufactured for : Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 05/21"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The available data from published case reports and the pharmacovigilance database on the use of omega-3-acid ethyl esters in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development when given at doses 5 times the maximum recommended human dose (MRHD) of 4 grams/day, based on a body surface area comparison. Omega-3-acid ethyl esters given orally to rats and rabbits during organogenesis was not teratogenic at clinically relevant exposures, based on body surface area comparison (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data: In female rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) beginning 2 weeks prior to mating through lactation, no adverse effects were observed at 2,000 mg/kg/day (5 times the MRHD based on body surface area [mg/m 2 ]). In a dose-ranging study, female rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) beginning 2 weeks prior to mating through Postpartum Day 7 had decreased live births (20% reduction) and pup survival to Postnatal Day 4 (40% reduction) at or greater than 3,000 mg/kg/day in the absence of maternal toxicity at 3,000 mg/kg/day (7 times the MRHD based on body surface area [mg/m 2 ]). In pregnant rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses at a maternally toxic dose (increased food consumption) of 6,000 mg/kg/day (14 times the MRHD based on body surface area [mg/m 2 ]). In pregnant rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) from Gestation Day 14 through Lactation Day 21, no adverse effects were observed at 2,000 mg/kg/day (5 times the MRHD based on body surface area [mg/m 2 ]). In pregnant rabbits given oral doses of omega-3-acid ethyl esters (375, 750, or 1,500 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses given 375 mg/kg/day (2 times the MRHD based on body surface area [mg/m 2 ]). However, at higher doses, increases in fetal skeletal variations and reduced fetal growth were evident at maternally toxic doses (reduced food consumption and body weight gain) greater than or equal to 750 mg/kg/day (4 times the MRHD), and embryolethality was evident at 1,500 mg/kg/day (7 times the MRHD). 8.2 Lactation Risk Summary Published studies have detected omega-3 fatty acids, including EPA and DHA, in human milk. Lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk. There are no data available on the effects of omega-3 fatty acid ethyl esters on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for omega-3-acid ethyl esters and any potential adverse effects on the breastfed child from omega-3-acid ethyl esters or from the underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use A limited number of subjects older than 65 years were enrolled in the clinical trials of omega-3-acid ethyl esters. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years."],"spl_patient_package_insert_table":["<table width=\"0px\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td valign=\"top\"><paragraph styleCode=\"first\"><content styleCode=\"bold\">PATIENT INFORMATION</content></paragraph><paragraph><content styleCode=\"bold\">Omega-3-acid ethyl esters</content></paragraph><paragraph><content styleCode=\"bold\">(oh-MAY-ga 3 AS-id eth-il es-ters)</content></paragraph><paragraph><content styleCode=\"bold\">Capsules, USP</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">What are omega-3-acid ethyl esters capsules? </content></paragraph><paragraph>Omega-3-acid ethyl esters capsules are a prescription medicine used along with a low-fat and low-cholesterol diet to lower very high triglyceride (fat) levels in adults.</paragraph><paragraph>It is not known if omega-3-acid ethyl esters changes your risk of having inflammation of your pancreas (pancreatitis).</paragraph><paragraph>It is not known if omega-3-acid ethyl esters prevents you from having a heart attack or stroke.</paragraph><paragraph>It is not known if omega-3-acid ethyl esters are safe and effective in children.</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">Who should not take omega-3-acid ethyl esters capsules? </content></paragraph><paragraph><content styleCode=\"bold\">Do not take omega-3-acid ethyl esters capsules </content>if you are allergic to omega-3-acid ethyl esters or any of the ingredients in omega-3-acid ethyl esters capsules. See the end of this leaflet for a complete list of ingredients in omega-3-acid ethyl esters capsules.</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking omega-3-acid ethyl esters, tell your healthcare provider about all of your medical conditions, including if you: </content></paragraph><list listType=\"unordered\"><item>have diabetes.</item><item>have a low thyroid problem (hypothyroidism).</item><item>have a liver problem.</item><item>have a pancreas problem.</item><item>have a certain heart rhythm problem called atrial fibrillation or flutter. </item><item>are allergic to fish or shellfish. It is not known if people who are allergic to fish or shellfish are also allergic to omega-3-acid ethyl esters capsules.</item><item>are pregnant or plan to become pregnant. It is not known if omega-3-acid ethyl esters will harm your unborn baby.</item><item>are breastfeeding or plan to breastfeed. Omega-3-acid ethyl esters can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take omega-3-acid ethyl esters capsules.</item></list><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph><paragraph>Omega-3-acid ethyl esters capsules can interact with certain other medicines that you are taking. Using omega-3-acid ethyl esters capsules with medicines that affect blood clotting (anticoagulants or blood thinners) may cause serious side effects.</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">How should I take omega-3-acid ethyl esters capsules? </content></paragraph><list listType=\"unordered\"><item>Take omega-3-acid ethyl esters capsules exactly as your healthcare provider tells you to take it.</item><item>You should not take more than 4 capsules of omega-3-acid ethyl esters capsules each day. Either take all 4 capsules at one time or 2 capsules two times a day.</item><item>Do not change your dose or stop omega-3-acid ethyl esters capsules without talking to your healthcare provider.</item><item>Take omega-3-acid ethyl esters capsules with food.</item><item>Take omega-3-acid ethyl esters capsules whole. Do not break, open, crush, dissolve, or chew omega-3-acid ethyl esters capsules before swallowing. If you cannot swallow omega-3-acid ethyl esters capsules whole, tell your healthcare provider. You may need a different medicine.</item><item>If you miss a dose of omega-3-acid ethyl esters capsules, take the missed dose as soon as you remember. If you miss one day of omega-3-acid ethyl esters capsules, <content styleCode=\"bold\">do not </content>double your dose the next time you take it.</item><item>Your healthcare provider may start you on a cholesterol-lowering diet before giving you omega-3-acid ethyl esters capsules. Stay on this diet while taking omega-3-acid ethyl esters capsules.</item><item>Your healthcare provider should do blood tests to check your triglyceride, bad cholesterol (LDL-C), and liver function (ALT and AST) levels while you take omega-3-acid ethyl esters capsules.</item></list></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">What are the possible side effects of omega-3-acid ethyl esters capsules? </content></paragraph><paragraph><content styleCode=\"bold\">Omega-3-acid ethyl esters capsules may cause serious side effects, including: </content></paragraph><list listType=\"unordered\"><item><content styleCode=\"bold\">changes in certain blood tests. </content>Omega-3-acid ethyl esters may cause an increase in the results of blood tests used to check your liver function and your bad cholesterol levels.</item><item><content styleCode=\"bold\">increased risk of a heart rhythm problem in people who have a heart rhythm problem. </content>Omega-3-acid ethyl esters may cause an increase in the frequency of a heart rhythm problem (atrial fibrillation or flutter), especially in the first few months of taking omega-3-acid ethyl esters, if you already have a heart rhythm problem.</item></list><paragraph>The most common side effects of omega-3-acid ethyl esters include:</paragraph><paragraph><renderMultiMedia referencedObject=\"L8f3a6905-d153-475b-b74c-ab9750ff3ad8\"/></paragraph><paragraph>These are not all the possible side effects of omega-3-acid ethyl esters. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store omega-3-acid ethyl esters capsules? </content></paragraph><list listType=\"unordered\"><item>Store omega-3-acid ethyl esters capsules at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item><item>Do not freeze omega-3-acid ethyl esters capsules.</item><item>Safely throw away medicine that is out of date or no longer needed.</item></list><paragraph><content styleCode=\"bold\">Keep omega-3-acid ethyl esters capsules and all medicines out of the reach of children.</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of omega-3-acid ethyl esters capsules. </content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use omega-3-acid ethyl esters capsules for a condition for which it was not prescribed. Do not give omega-3-acid ethyl esters capsules to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about omega-3-acid ethyl esters capsules that is written for health professionals.</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in omega-3-acid ethyl esters capsules, USP? </content></paragraph><paragraph>Active Ingredient: omega-3-acid ethyl esters, mostly EPA and DHA.</paragraph><paragraph>Inactive Ingredients: gelatin, glycerin, 4.4 mg &#x3B1;-tocopherol, soybean oil and purified water. The capsules are printed with white imprinting ink containing titanium dioxide, hypromellose 2910 and propylene glycol.</paragraph></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">Manufactured by</content>:</paragraph><paragraph>Ascent Pharmaceuticals, Inc.</paragraph><paragraph>Central Islip, NY 11722</paragraph><paragraph><content styleCode=\"bold\">Manufactured for</content>:</paragraph><paragraph>Camber Pharmaceuticals, Inc.</paragraph><paragraph>Piscataway, NJ 08854</paragraph></td></tr></tbody></table>"],"package_label_principal_display_panel":["Omega-3-Acid Ethyl Esters 1 g Cap#120 Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated with omega-3-acid ethyl esters for 101 weeks and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 grams/day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice. Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without metabolic activation in the bacterial mutagenesis (Ames) test with Salmonella typhimurium and Escherichia coli or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Omega-3-acid ethyl esters were negative in the in vivo mouse micronucleus assay. In a rat fertility study with oral doses of 100, 600, and 2,000 mg/kg/day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to mating and through lactation. No adverse effect on fertility was observed at 2,000 mg/kg/day (5 times the MRHD of 4 grams/day based on body surface area [mg/m 2 ])."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FLUSHING","source":"FDA FAERS","actionTaken":"1031 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"856 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"784 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"781 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"743 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"657 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"652 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"633 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"623 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"557 reports"}],"drugInteractions":[{"drug":"anticoagulants or other drugs affecting coagulation (e.g., anti-platelet agents)","severity":"moderate","mechanism":"Omega-3-acids may prolong bleeding time.","management":"Patients should be monitored periodically.","clinicalEffect":"Prolongation of bleeding time, which has not exceeded normal limits and did not produce clinically significant bleeding episodes."}],"commonSideEffects":[{"effect":"Taste perversion","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Eructation","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastrointestinal disorder","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased ALT","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased AST","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters or any of its components."],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Anaphylactic reaction","drugRate":"","severity":"serious"},{"effect":"Hemorrhagic diathesis","drugRate":"","severity":"serious"},{"effect":"Urticaria","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["EPA+DHA supplements (OmegaRx)"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=omega","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:17:50.808227+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:17:58.976212+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T02:17:49.375117+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=omega","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:17:59.713568+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:17:48.244698+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:18:22.668301+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:17:48.244747+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T02:18:01.400009+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:18:14.929053+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1651027/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:18:00.264495+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:18:07.276394+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA207420","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:17:48.244755+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"21cfa4ce-0b05-47ed-b268-339eb1b83b75","title":"LOVAZA (OMEGA-3-ACID ETHYL ESTERS) CAPSULE [WAYLIS THERAPEUTICS LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-27T23:35:19.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:18:22.936188+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"id":"omega-severe-hypertriglyceridemia","name":"Severe Hypertriglyceridemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with severe (≥500 mg/dL) hypertriglyceridemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with severe (≥500 mg/dL) hypertriglyceridemia","diagnosticRequired":"Triglyceride level ≥500 mg/dL","brandNameForIndication":""}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT06883422","phase":"NA","title":"Pre-Surgical Immunonutrition's Effect on Colorectal Surgery","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2023-05-25","conditions":"Colorectal Surgery","enrollment":126},{"nctId":"NCT04031508","phase":"PHASE2","title":"Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH","status":"ENROLLING_BY_INVITATION","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2019-08-12","conditions":"Pulmonary Hypertension of Newborn, Diaphragm Defect","enrollment":40},{"nctId":"NCT05297279","phase":"NA","title":"OMEGA - Dietary Intervention - COPD Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-03-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT05602194","phase":"PHASE3","title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-08-14","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","enrollment":440},{"nctId":"NCT07391254","phase":"NA","title":"Omega-3 Supplementation and Mental Health in College Students","status":"COMPLETED","sponsor":"University of Colorado, Colorado Springs","startDate":"2024-08-29","conditions":"Mental Health, Vitamin D","enrollment":103},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT06434948","phase":"PHASE2","title":"The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"University of Missouri-Columbia","startDate":"2026-03-03","conditions":"Postoperative Delirium","enrollment":90},{"nctId":"NCT04716699","phase":"PHASE1","title":"Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-01-20","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT06931977","phase":"NA","title":"Natural Product System and Lifestyle Modification","status":"COMPLETED","sponsor":"dōTERRA International","startDate":"2025-04-29","conditions":"Healthy","enrollment":97},{"nctId":"NCT05044468","phase":"PHASE2","title":"EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-23","conditions":"Malignant Pleural Neoplasm","enrollment":80},{"nctId":"NCT06123286","phase":"EARLY_PHASE1","title":"Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms","status":"RECRUITING","sponsor":"Philip Chang","startDate":"2025-09-12","conditions":"Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain","enrollment":30},{"nctId":"NCT07439601","phase":"NA","title":"Long-Term Omega-3 and Omega-3 Index >8%: Effects on Physiological Recovery","status":"NOT_YET_RECRUITING","sponsor":"St. Mary's University, Twickenham","startDate":"2026-02-28","conditions":"Focus on Omega 3 Index on Recovery","enrollment":46},{"nctId":"NCT06057597","phase":"NA","title":"Omega Gastric Bypass (150cm) Compared to the Roux-en-Y Gastric Bypass (YOMEGA-2 Multicentric Trial)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-13","conditions":"Obesity, Morbid","enrollment":368},{"nctId":"NCT07216001","phase":"PHASE2","title":"Role of Omega-DEK in Childhood Apraxia of Speech","status":"NOT_YET_RECRUITING","sponsor":"Claudia R. Morris","startDate":"2026-05","conditions":"Childhood Apraxia of Speech, Verbal Apraxia, Autism","enrollment":34},{"nctId":"NCT06899074","phase":"NA","title":"Omega-3 Supplementation for Pediatric Migraine","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-04-17","conditions":"Migraine","enrollment":58},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT06802068","phase":"NA","title":"Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement","status":"COMPLETED","sponsor":"Hofseth Biocare ASA","startDate":"2025-02-18","conditions":"Supplementation in Healthy Adults to Assess Impact on Omega 3 Index and Cardiometabolic Health","enrollment":96},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT06991296","phase":"NA","title":"Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-06-02","conditions":"Obesity","enrollment":33},{"nctId":"NCT05774665","phase":"PHASE2","title":"Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-01-30","conditions":"Treatment Resistant Depression, Inflammation, Overweight","enrollment":80},{"nctId":"NCT03699995","phase":"NA","title":"MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2018-05-18","conditions":"Cutaneous Melanoma, Melanocytic Nevus, Skin Carcinoma","enrollment":100},{"nctId":"NCT07388108","phase":"","title":"Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery.","status":"RECRUITING","sponsor":"School of Medicine. National University of Cuyo","startDate":"2026-02-06","conditions":"Atrial Fibrillation, Postoperative Complications","enrollment":138},{"nctId":"NCT07399743","phase":"PHASE3","title":"Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Badr University","startDate":"2026-02-15","conditions":"Knee Osteoarthritis","enrollment":160},{"nctId":"NCT07394517","phase":"NA","title":"ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3","status":"NOT_YET_RECRUITING","sponsor":"Fundación del Caribe para la Investigación Biomédica","startDate":"2026-03","conditions":"Mixed Dyslipidemia","enrollment":105},{"nctId":"NCT07371416","phase":"NA","title":"Regenerative Root Canal Treatment of Immature Teeth Using Omega-3 Fatty Acids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2025-10-01","conditions":"Immature Permanent Teeth With Open Apex, Pulp Necrosis","enrollment":20},{"nctId":"NCT05758766","phase":"NA","title":"Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-08-30","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT05069402","phase":"NA","title":"Impact of Various Diets on Surgical Complications","status":"COMPLETED","sponsor":"Stanley Dudrick's Memorial Hospital","startDate":"2021-09-01","conditions":"Complication,Postoperative","enrollment":300},{"nctId":"NCT07331103","phase":"NA","title":"RESOLving INflammation Through Diet for Health (RESOLVIN)","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-11-26","conditions":"Cardiovascualr Disease, Lipids, Inflammation","enrollment":324},{"nctId":"NCT07314593","phase":"NA","title":"Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.","status":"NOT_YET_RECRUITING","sponsor":"Landspitali University Hospital","startDate":"2025-12-19","conditions":"Respiratory Infections","enrollment":400},{"nctId":"NCT05640843","phase":"NA","title":"A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-29","conditions":"Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma","enrollment":150},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT04930029","phase":"","title":"Evaluation of Long-term Adverse Effects of Gastric Bypass in Omega","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2021-09-15","conditions":"Bypass Complication, Obesity","enrollment":320},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT02139813","phase":"NA","title":"Omega Loop Versus Roux-en-Y Gastric Bypass","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-05","conditions":"Obesity","enrollment":256},{"nctId":"NCT07226414","phase":"NA","title":"Prenatal Study in Healthy Pregnant Women","status":"RECRUITING","sponsor":"Perelel Inc.","startDate":"2025-12-01","conditions":"Pregnancy","enrollment":40},{"nctId":"NCT04745910","phase":"PHASE4","title":"Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome","enrollment":10},{"nctId":"NCT06751810","phase":"NA","title":"Nutritional Status in Children With Food Allergy: Evaluation of a New Supplement","status":"COMPLETED","sponsor":"Federico II University","startDate":"2024-12-30","conditions":"Food Allergies","enrollment":30},{"nctId":"NCT07289919","phase":"NA","title":"Exploring Sustainable Alternatives to Marine Oils With Echium and Ahiflower Oils","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-05-26","conditions":"Cardiovascular (CV) Risk, Atheroscleroses, Inflamation","enrollment":15},{"nctId":"NCT02445651","phase":"NA","title":"Physiological Effects of Nutritional Support in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2014-03","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":51},{"nctId":"NCT07265076","phase":"","title":"Role of Omega-6 Fatty Acids in Hepatocellular Carcinoma Development.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-12-01","conditions":"Carcinoma, Hpatocellular","enrollment":100},{"nctId":"NCT04499820","phase":"NA","title":"Effect of OMEGA3 Supplementation in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2020-06-26","conditions":"Diabetic Retinopathy","enrollment":60},{"nctId":"NCT07265063","phase":"NA","title":"Pulpotomy With CEM vs Pulpectomy With Ca(OH)2/Iodoform in Primary Molars","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-12-01","conditions":"Carious Primary Molars","enrollment":50},{"nctId":"NCT06621979","phase":"NA","title":"Evaluation of the Fundoplicature of the Excluded Stomach Post Omega Bypass","status":"RECRUITING","sponsor":"GCS Ramsay Santé pour l'Enseignement et la Recherche","startDate":"2025-11-24","conditions":"Bypass, Gastric","enrollment":17},{"nctId":"NCT04829929","phase":"NA","title":"Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eclipse Medical Ltd.","startDate":"2020-11-17","conditions":"Non-Valvular Atrial Fibrillation","enrollment":200},{"nctId":"NCT03625349","phase":"","title":"Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2015-09-01","conditions":"Aging, Cardiovascular Disease","enrollment":130},{"nctId":"NCT07255326","phase":"NA","title":"Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes","status":"RECRUITING","sponsor":"University of Faisalabad","startDate":"2025-10-01","conditions":"Diabetic Retinopathy, Type 1 Diabetes, Omega 3 Fatty Acids","enrollment":80},{"nctId":"NCT05034627","phase":"PHASE1","title":"Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-08-09","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":15},{"nctId":"NCT07241377","phase":"PHASE3","title":"A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo","status":"RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-10-27","conditions":"Absorption of Omega-3, Omega-3 Supplementation, Healthy Participants","enrollment":120},{"nctId":"NCT07237113","phase":"NA","title":"Muscle Recovery After Omega-3 Supplementation","status":"COMPLETED","sponsor":"Instituto de Ciencias de la Salud, Universidad de O'Higgins","startDate":"2021-09-01","conditions":"Damage Muscle","enrollment":30},{"nctId":"NCT06629103","phase":"PHASE4","title":"A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA","status":"ACTIVE_NOT_RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-08-06","conditions":"Optimal Absorption of Omega-3, Healthy","enrollment":120},{"nctId":"NCT04312932","phase":"PHASE2","title":"Fatty Acid Supplementation in Children With ASD (Study 2)","status":"COMPLETED","sponsor":"Sarah Keim","startDate":"2021-12-01","conditions":"Autism Spectrum Disorder","enrollment":98},{"nctId":"NCT06055894","phase":"NA","title":"A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-20","conditions":"Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance","enrollment":200},{"nctId":"NCT07206134","phase":"NA","title":"Evaluation of Modified Omega Plate in the Management of Mandibular Fractures Compared With Conventional Fixation","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-03-01","conditions":"Mandibular Fractures, Fracture in Mental Nerve Region","enrollment":12},{"nctId":"NCT07206719","phase":"NA","title":"Safety and Efficacy of Concurrent MACE and Mitrofanoff Procedures","status":"COMPLETED","sponsor":"Mohammad Daboos","startDate":"2022-01-01","conditions":"Fecal Incontinence, Urinary Incontinence","enrollment":30},{"nctId":"NCT07130513","phase":"NA","title":"Investigating the Feasibility of Krill Oil Intervention to Improve Muscle Function in Adults With Long-term Conditions","status":"RECRUITING","sponsor":"University of Glasgow","startDate":"2025-08-18","conditions":"Krill Oil, Muscle Function, Grip Strength","enrollment":30},{"nctId":"NCT05137132","phase":"NA","title":"Unrefined Salmon Oil as Dietary Supplement in Adult Asthmatics","status":"COMPLETED","sponsor":"Hofseth Biocare ASA","startDate":"2022-04-01","conditions":"Asthma","enrollment":70},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT05130294","phase":"NA","title":"Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Hofseth Biocare ASA","startDate":"2025-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT03869957","phase":"NA","title":"Effect of Parenteral Nutrition With n-3 PUFAs on Patients With Intestinal Failure","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2019-12-01","conditions":"Intestinal Failure","enrollment":20},{"nctId":"NCT05248737","phase":"","title":"Bioavailability of Vitamin D(25(OH)D) and Omega-3 Fatty Acid (DHA) Enhanced Chicken","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cornell University","startDate":"2021-12-04","conditions":"Nutrition, Healthy","enrollment":84},{"nctId":"NCT04553705","phase":"PHASE2, PHASE3","title":"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2020-09-20","conditions":"Covid19, Immunodeficiency","enrollment":150},{"nctId":"NCT06874959","phase":"NA","title":"Evaluation of the Pain Relief Effect of Battlefield Acupuncture on Patients With Chronic Low Back Pain Due to Lumbar Spine Degeneration.","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2025-03-15","conditions":"Spondylosis Lumbar","enrollment":60},{"nctId":"NCT07163208","phase":"NA","title":"Therapeutic Efficacy of Different Wavelengths of Low-Level Laser Therapy in the Treatment of Cervicogenic Headache","status":"RECRUITING","sponsor":"University of Lahore","startDate":"2024-09-05","conditions":"Cervicogenic Headache","enrollment":150},{"nctId":"NCT03406897","phase":"PHASE1, PHASE2","title":"Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients","status":"COMPLETED","sponsor":"Rodolfo Alejandro","startDate":"2018-07-23","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus","enrollment":27},{"nctId":"NCT02295059","phase":"NA","title":"Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-08-09","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT02523118","phase":"","title":"OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-07-17","conditions":"Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis","enrollment":1350},{"nctId":"NCT06807346","phase":"NA","title":"Evaluating the Efficacy of the Study Product on Overall Cognitive Function in Children","status":"COMPLETED","sponsor":"SmartyPants Vitamins Inc.","startDate":"2025-05-06","conditions":"Cognition","enrollment":120},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT04793035","phase":"NA","title":"Omega Cuff for GERD Feasibility Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aplos Medical","startDate":"2023-08-08","conditions":"GERD, Acid Reflux, Treatment","enrollment":8},{"nctId":"NCT06896201","phase":"NA","title":"Comfortage - AD Prevention Strategies","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09","conditions":"Alzheimer Disease, Subjective Cognitive Impairment, Mild Cognitive Impairment","enrollment":200},{"nctId":"NCT07138131","phase":"NA","title":"Impact of Omega 3 in Treatment of Inappropriate Sinus Tachycardia","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-10-01","conditions":"Omega 3, Treatment, Inappropriate Sinus Tachycardia","enrollment":60},{"nctId":"NCT07133477","phase":"NA","title":"A Study to Evaluate the Effect of Fish Oil Concentrate on Skin Function","status":"RECRUITING","sponsor":"Epax Norway AS","startDate":"2025-04-30","conditions":"Skin Health","enrollment":90},{"nctId":"NCT07127068","phase":"NA","title":"Investigation of the Effects of Omega-3 Supplementation in Chronic Kidney Disease Patients Diagnosed With Coronary Artery Disease and Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Beykent","startDate":"2024-06-01","conditions":"Omega 3 Fatty Acids, Coronary Arterial Disease (CAD), Chronic Kidney Disease(CKD)","enrollment":60},{"nctId":"NCT07118059","phase":"PHASE2","title":"Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial","status":"NOT_YET_RECRUITING","sponsor":"North-West University, South Africa","startDate":"2025-08","conditions":"Tuberculosis, Inflammation Biomarkers, Liver Function Tests","enrollment":40},{"nctId":"NCT04627701","phase":"NA","title":"Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH","status":"RECRUITING","sponsor":"ProArc Medical","startDate":"2023-07-23","conditions":"Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms","enrollment":26},{"nctId":"NCT05757687","phase":"NA","title":"Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH","status":"RECRUITING","sponsor":"ProArc Medical","startDate":"2023-02-07","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":11},{"nctId":"NCT02348073","phase":"PHASE3","title":"Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-03","conditions":"Attention Deficit Disorder With Hyperactivity, ADHD Inattention or Mixed Type, Epilepsy","enrollment":77},{"nctId":"NCT05961800","phase":"NA","title":"Offset Mechanisms in Evaluation of Lumbar Medial Branch Blocks","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2023-07-05","conditions":"Pain, Chronic, Facet Joint Pain, Pain, Procedural","enrollment":40},{"nctId":"NCT06832787","phase":"NA","title":"Evaluation of Combinational Use of Negative Pressure Wound Therapy (NPWT) for Diabetic Foot Wounds","status":"RECRUITING","sponsor":"Singapore General Hospital","startDate":"2025-07-22","conditions":"Diabetic Foot Ulcer","enrollment":75},{"nctId":"NCT07036952","phase":"NA","title":"Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome.","status":"ENROLLING_BY_INVITATION","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-04-22","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":68},{"nctId":"NCT07048860","phase":"NA","title":"ICOPE INTENSE-K Pilot Study","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-07-09","conditions":"Ageing","enrollment":40},{"nctId":"NCT07071272","phase":"NA","title":"Non-inferiority Study of Contrast-enhanced Digital Mammography (CEDM) vs Magnetic Resonance Imaging (MRI) in Terms of Diagnostic Accuracy in Patients Undergoing Preoperative Staging of Established Invasive Breast Cancer","status":"RECRUITING","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2020-09-01","conditions":"Breast Cancer","enrollment":216},{"nctId":"NCT07067515","phase":"PHASE1, PHASE2","title":"Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suez Canal University","startDate":"2024-01-03","conditions":"Hyperpigmentation, Gingival Hyperpigmentaion","enrollment":30},{"nctId":"NCT07056257","phase":"NA","title":"Adjunct Use of Diode Laser Therapy and Omega 3 Gel in Local Drug Delivery Approach on The Treatment of Localized Aggressive Periodontitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-05-08","conditions":"Diode Laser Therapy, Omega 3, Localized Aggressive Periodontitis","enrollment":52},{"nctId":"NCT06125782","phase":"PHASE2","title":"Effect of Omega-3 Fatty Acid on Neurobehavioral Status of Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Trial","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-09-19","conditions":"Autism Spectrum Disorder","enrollment":64},{"nctId":"NCT06630637","phase":"NA","title":"Monitoring Intermittent Fasting for Human Optimization Using Wearable Technology: An N-of-1 Study","status":"COMPLETED","sponsor":"Institute for Digital Medicine (WisDM)","startDate":"2024-10-07","conditions":"Intermittent Fasting, Healthy, Digital Health","enrollment":1},{"nctId":"NCT04763291","phase":"NA","title":"Cardiovascular and InflammAging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Green Beat","startDate":"2021-09-01","conditions":"Aging, Cardiovascular Diseases, Overweight or Obesity","enrollment":80},{"nctId":"NCT02986672","phase":"NA","title":"Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)","status":"COMPLETED","sponsor":"University Hospital of North Norway","startDate":"2017-11-03","conditions":"ADHD, ADD","enrollment":332},{"nctId":"NCT06505408","phase":"NA","title":"Impact of a MVM to Support Biomarkers Associated With Conception and Pregnancy in Healthy Women.","status":"COMPLETED","sponsor":"Perelel Inc.","startDate":"2024-10-02","conditions":"Healthy Adult Women of Child Bearing Age","enrollment":60},{"nctId":"NCT06995586","phase":"NA","title":"Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","status":"NOT_YET_RECRUITING","sponsor":"Nicosia General Hospital","startDate":"2025-09-01","conditions":"Cardio-pulmonary Bypass, Cardiovascular Diseases, Omega-3 Polyunsaturated Fatty Acids","enrollment":108},{"nctId":"NCT00678743","phase":"PHASE4","title":"An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2007-08","conditions":"Dyslipidemias","enrollment":17},{"nctId":"NCT06992323","phase":"NA","title":"Cardiometabolic Properties of Omega-3 Functionalized With Hydroxytyrosol","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Research Council, Spain","startDate":"2025-02-17","conditions":"Hypertriglyceridemia, Normal","enrollment":68},{"nctId":"NCT04222660","phase":"NA","title":"Corneal Nerves Function and Structure","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-06-21","conditions":"Diabetic Peripheral Neuropathy","enrollment":44},{"nctId":"NCT01791816","phase":"EARLY_PHASE1","title":"Mechanisms of Vasovagal Syncope","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-02","conditions":"Vasovagal Syncope, Postural Tachycardia Syndrome","enrollment":90},{"nctId":"NCT06981676","phase":"NA","title":"The Developmental Origins of Obesity","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2023-07-25","conditions":"Maternal Obesity, Obesity","enrollment":160},{"nctId":"NCT06665464","phase":"NA","title":"Bioavailability of Omega-3 Fatty Acids From Fish Oil Supplements","status":"COMPLETED","sponsor":"Wageningen University and Research","startDate":"2024-11-20","conditions":"Nutrition, Absorption, Metabolism and Excretion in Healthy Volunteers, Fish Oils","enrollment":12},{"nctId":"NCT05191823","phase":"NA","title":"Omega Tots Long Term Follow-up","status":"ENROLLING_BY_INVITATION","sponsor":"Sarah Keim","startDate":"2021-12-01","conditions":"Preterm Birth, Child Development","enrollment":377}],"_emaApprovals":[],"_faersSignals":[{"count":4254,"reaction":"FATIGUE"},{"count":3139,"reaction":"NAUSEA"},{"count":3105,"reaction":"DIARRHOEA"},{"count":2937,"reaction":"DRUG INEFFECTIVE"},{"count":2858,"reaction":"HEADACHE"},{"count":2488,"reaction":"PAIN"},{"count":2398,"reaction":"ARTHRALGIA"},{"count":2360,"reaction":"DIZZINESS"},{"count":2160,"reaction":"DYSPNOEA"},{"count":2076,"reaction":"OFF LABEL USE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL1651027"},"formularyStatus":[],"_approvalHistory":[{"date":"20200224","type":"SUPPL","sponsor":"AMNEAL PHARMS","applicationNumber":"ANDA204940"},{"date":"20210106","type":"SUPPL","sponsor":"AMNEAL PHARMS","applicationNumber":"ANDA204940"},{"date":"20151127","type":"ORIG","sponsor":"AMNEAL PHARMS","applicationNumber":"ANDA204940"},{"date":"20211115","type":"ORIG","sponsor":"MANKIND PHARMA","applicationNumber":"ANDA215458"},{"date":"20200402","type":"SUPPL","sponsor":"GLW","applicationNumber":"ANDA091028"},{"date":"20140625","type":"SUPPL","sponsor":"GLW","applicationNumber":"ANDA091028"},{"date":"20140407","type":"ORIG","sponsor":"GLW","applicationNumber":"ANDA091028"},{"date":"20210106","type":"SUPPL","sponsor":"GLW","applicationNumber":"ANDA091028"},{"date":"20201002","type":"SUPPL","sponsor":"ONESOURCE SPECIALTY","applicationNumber":"ANDA203893"},{"date":"20170919","type":"ORIG","sponsor":"ONESOURCE SPECIALTY","applicationNumber":"ANDA203893"},{"date":"20201002","type":"SUPPL","sponsor":"ONESOURCE SPECIALTY","applicationNumber":"ANDA203893"},{"date":"20200309","type":"SUPPL","sponsor":"ONESOURCE SPECIALTY","applicationNumber":"ANDA203893"},{"date":"20190225","type":"ORIG","sponsor":"ASCENT PHARMS INC","applicationNumber":"ANDA207420"},{"date":"20210106","type":"SUPPL","sponsor":"ASCENT PHARMS INC","applicationNumber":"ANDA207420"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":68907,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"omega","genericName":"omega","companyName":"Gachon University Gil Medical Center","companyId":"gachon-university-gil-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-11-27T00:00:00.000Z","mah":"AMNEAL PHARMS","brand_name_local":null,"application_number":"ANDA204940"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-07T00:00:00.000Z","mah":"CHARTWELL","brand_name_local":null,"application_number":"ANDA206455"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-03-09T00:00:00.000Z","mah":"ONESOURCE SPECIALTY","brand_name_local":null,"application_number":"ANDA203893"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-01-06T00:00:00.000Z","mah":"GLW","brand_name_local":null,"application_number":"ANDA091028"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-11-15T00:00:00.000Z","mah":"MANKIND PHARMA","brand_name_local":null,"application_number":"ANDA215458"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:18:22.936188+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}